Proinflammatory mediators and migraine pathogenesis: Moving towards CGRP as a target for a novel therapeutic class

Expert Review of Neurotherapeutics

Volumn 8, Issue 9, 2008, Pages 1347-1354

  Farinelli, Ivano ^a   Missori, Serena ^a   Martelletti, Paolo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CGRP antagonist; COXIB; Migraine; NSAID; Telcagepant

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMIGRAINE AGENT; BIB 4096; CAFFEINE; CALCITONIN GENE RELATED PEPTIDE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC POTASSIUM; ELETRIPTAN; ERGOT DERIVATIVE; ERGOTAMINE; IBUPROFEN; LYSINE ACETYLSALICYLATE; MK 0974; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OLCEGEPANT; PARACETAMOL; RIZATRIPTAN; ROFECOXIB; SUMATRIPTAN; TELCAGEPANT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ASTHMA; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; MENSTRUAL MIGRAINE; MIGRAINE; MONOTHERAPY; NAUSEA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHONOPHOBIA; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RISK FACTOR; SOMNOLENCE; THORAX PAIN; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCITONIN GENE-RELATED PEPTIDE; CLINICAL TRIALS AS TOPIC; DIPEPTIDES; HUMANS; MIGRAINE DISORDERS; QUINAZOLINES; TRYPTAMINES;

EID: 51149090168     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.9.1347     Document Type: Review

References (94)

1. Piane M, Lulli P, Farinelli I et al. Genetics of migraine and pharmacogenomics: some considerations. J. Headache Pain 8(6), 334-339 (2007).
2. Montagna P. The primary headaches: genetics, epigegenetics and behavoural genetic model. J. Headache Pain 9(2), 57-69 (2008).
3. Tfelt-Hansen P, Brøsen K. Pharmacoeconomics and migraine: possible implications. J. Headache Pain 9(1), 13-18 (2008).
4. Martelletti P, Steiner TJ, Bertolote JM, Dua T, Saraceno B. The definitive position of headache among the major public health challenges. An end to the slippery slope of disregard. J. Headache Pain 8(3), 149-151 (2007). • First collaborative publication on the results of the WHO Global Campaign to Reduce the Burden of Headache Worldwide.
5. Breslau N, Rasmussen BK. The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology 56(Suppl. 1), 4-12 (2001).
6. 3 receptors by the migraine mediators CGRP and NGF. Mol. Neurobiol. 37(1), 83-90 (2008).
7. 1 receptor signaling. Mol. Pain 16(4), 12 (2008).
8. Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache 46(Suppl. 1), 3-8 (2006).
9. Blandini F, Rinaldi L, Tassorelli C et al. Peripheral levels of BDNF and NGF in primary headaches. Cephalalgia 26(2), 136-142 (2006).
10. Sakai Y, Dobson C, Diksic M, Aubé M, Hamel E. Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology 70(6), 431-439 (2008).
11. Bruno PP, Carpino F, Carpino G, Zicari A. An overview on immune system and migraine. Eur. Rev. Med. Pharmacol. Sci. 11(4), 245-248 (2007).
12. Fidan I, Yüksel S, Ymir T, Irkeç C, Aksakal FN. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J. Neuroimmunol. 171(1-2), 184-188 (2006).
13. Rapoport AM. Acute treatment of headache. J. Headache Pain 7(5), 355-359 (2006).
14. Farinelli I, Martelletti P. Aspirin and tension-type headache. J. Headache Pain 8(1), 49-55 (2007).
15. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231(25), 232-235 (1971).
16. De Witt DL, El-Harith EA, Kraemer SA et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem. 265(9), 5192-5198 (1990).
17. Smith WL, De Witt DL. Prostaglandin endoperoxide H synthases 1 and -2. Adv. Immunol. 62, 167-215 (1996).
18. Martelletti P, Farinelli I, Coloprisco G, Patacchioli FR. Role of NSAIDs in acute treatment of headache. Drug Dev. Res. 68, 276-281(2007). • Comprehensive review of the wide spectrum of NSAIDs used in migraine attacks.
19. Schoenen J. When should triptans be taken during a migraine attack? CNS Drugs 15(8), 583-587(2001).
20. Goldstein J, Silberstein S, Saper JR et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache 45(8), 973-982 (2005).
21. Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN. Aspirin is efficacious for the treatment of acute migraine. Headache 45(4), 283-292(2005).
22. Pfaffenrath V, Scherzer S. Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalalgia 15(Suppl. 15), 14-20(1995).
23. MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache 42(4), 249-255 (2002).
24. Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared with subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia 19(6), 581-588 (1999).
25. Codispoti JR, Prior MJ, Fu M, Harte CM, Nelson EB. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache 41(7), 665-679 (2001).
26. Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac.potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 19(4), 232-240 (1999).
27. Smith TR, Sunshine A, Stuart RS, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 45(8), 983-991 (2005).
28. Saper J, Dahlof C, So Y et al. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial. Headache 46(2), 264-275 (2006).
29. Von Seggern RL, Mannix LK, Adelman JU. Rofecoxib in the prevention of perimenstrual migraine: an open-label pilot trial. Headache 44(2), 160-165 (2004).
30. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 264(13), 1711-1713 (1990).
31. Hernández-Diaz S, García-Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 4(20), 22 (2006).
32. Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke 36(8), 1801-1807 (2005).
33. Serebruany VL, Stenhubl SR, Berger PB et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am. J. Cardiol. 95(10), 1218-1222 (2005).
34. Baldassarre S, Schandene L, Choufani G, Michils A. Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen. J. Allergy Clin. Immunol. 117(1), 215-217 (2006).
35. Diener HC, Bussone G, de Liano H et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 24(11), 947-954 (2004).
36. Mathew NT. Transformed migraine. Cephalalgia 13(Suppl. 12), 78-83 (1993).
37. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd Edition. Cephalalgia 24(Suppl. 1), 9-160 (2004).
38. Saper JR, Hamel RL, Lake AE 3rd. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia 25(7), 545-546 (2005).
39. Radat F, Creac'h C, Swendsen JD et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 25(7), 519-522 (2005).
40. Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rate and predictors for relapse in medication overuse headache: a one year prospective study. Neurology 60(10), 1682-1684 (2003).
41. Katsarava Z, Müssig M, Dzagnidze A, Frische G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4 year prospective study. Cephalalgia 25(1), 12-15 (2005).
42. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60(6), 1259-1287 (2000).
43. Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 48(2), 236-247 (2008).
44. Adelman JU, Lipton RB, Ferrari MD et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 57(8), 1377-1383 (2001).
45. Misra UK, Kalita J, Yadav RK. Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. J. Headache Pain 8(3), 175-179 (2007).
46. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22(8), 633-658 (2002).
47. Tfelt-Hansen P. Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment. J. Headache Pain 8(5), 273-276 (2007).
48. Panconesi A, Pavone E, Vacca F, Vaiani M, Banfi R. Triptans in the Italian population: a drug utilization study and a literature review. J. Headache Pain 9(2), 71-76 (2008).
49. Dodick DW, Papademetriou V. Cardiovascular safety of triptans. Cephalalgia 24(7), 513-514(2004).
50. Houghton LA, Foster J, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet 344(8928), 985-986 (1994).
51. Boska MD, Welch KM, Schultz L, Nelson J. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. Cephalalgia 20(1), 39-44 (2000).
52. MacLean MR, Clayton RA, Templeton AG, Morecroft I. Evidence for 5-HT-1-like receptor-mediated vasoconstrictionin human pulmonary artery. Br. J. Pharmacol. 119(2), 277-282(1996).
53. Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG. Contribution of central sensitization to the development of non-cardiac chest pain. Lancet 356(9236), 1154-1159 (2000).
54. Goldstein JA, Massey KD, Kirby S et al. Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia 24(7), 515-521 (2004).
55. Messlinger K, Hanesch U, Kurosawa M, Pawlak M, Schmidt RF. Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat. Can. J. Physiol. Pharmacol. 73(7), 1020-1024 (1995).
56. Sun RQ, Tu YJ, Lawand NB, Yan JY, Lin Q, Willis WD. Calcitonin gene-related peptide receptor activation produces PKA- and PKC-dependent mechanical hyperalgesia and central sensitization. J. Neurophysiol. 92(5), 2859-2866 (2004).
57. Edvinsson L, Sams A, Jansen-Olesen I et al. Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur. J. Pharmacol. 415(1), 39-44 (2001).
58. Lennerz JK, Rühle V, Ceppa EP et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J. Comp. Neurol. 507(3), 1277-1299 (2008).
59. Conner AC, Hay DL, Howitt SG et al. Interaction of calcitonin-gene-related peptide with its receptors. Biochem. Soc. Trans. 30(4), 451-455 (2002).
60. Saetrum Opgaard O, de Vries R, Tom B, Edvinsson L, Saxena PR. Positive inotropy of calcitonin gene-related peptide and amylin on porcine isolated myocardium. Eur. J. Pharmacol. 385(2-3), 147-154 (1999).
61. Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J. Headache Pain 9(1), 5-12 (2008). • In-depth overview of the current status of CGRP antagonists for migraine.
62. Arulmani U, Maassenvandenbrink A, Villalón CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur. J. Pharmacol. 500(1-3), 315-330 (2004).
63. Buzzi MG. Reading data in migraine acute treatment studies: from clinical trials to reviews and meta-analyses. J. Headache Pain 7(3), 160-164 (2006).
64. Ma W, Chabot JG, Powell KJ, Jhamandas K, Dickerson IM, Quirion R. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience 120(3), 677-694 (2003).
65. Buzzi MG, Moskovitz MA. The pathophysiology of migraine: year 2005. J. Headache Pain 6(3), 105-111 (2005). • Migraine mechanics as discovered by the most important area scientist.
66. 1B/1D receptor towards CGRP receptors.
67. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 31(6), 365-371 (1991).
68. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 22(1), 54-61 (2002).
69. Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia 14(5), 320-327 (1994).
70. Limmroth V, Katsarava Z, Liedert B et al. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain 92(1-2), 101-106 (2001).
71. Diener HC, Limmroth V. Acute management of migraine: triptans and beyond. Curr. Opin. Neurol. 12(3), 261-267 (1999).
72. Yun HY, Dawson VL, Dawson TM. Neurobiology of nitric oxide. Crit. Rev. Neurobiol. 10(3-4), 291-316 (1996).
73. Faraci F, Heistad D. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol. Rev. 78(1), 53-97 (1998).
74. Li J, Vause CV, Durham PL. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res. 1196, 22-32 (2008).
75. Thalakoti S, Patil VV, Damodaram S et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47(7), 1008-1023 (2007).
76. Eberhardt M, Hoffmann T, Sauer SK, Messlinger K, Reeh PW, Fischer MJ. Calcitonin gene-related peptide release from intact isolated dorsal root and trigeminal ganglia. Neuropeptides 42(3), 311-317 (2008).
77. Juhasz G, Zsombok T, Modos EA et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106(3), 461-470 (2003).
78. Kruuse C, Frandsen E, Schifter S, Thomsen LL, Birk S, Olesen J. Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. Cephalalgia 24(7), 547-553 (2004).
79. Eikermann-Haerter K, Kudo C, Moskowitz MA. Cortical spreading depression and estrogen. Headache 47(Suppl. 2), 79-85 (2007).
80. Shimizu T, Toriumi H, Sato H et al. Distribution and origin of TRPV1 receptor-containing nerve fibers in the dura mater of rat. Brain Res. 1173, 84-91 (2007).
81. Helliwell RJ, McLatchie LM, Clarke M, Winter J, Bevan S, McIntyre P. Capsaicin sensitivity is associated with the expression of the vanilloid (capsaicin) receptor (VR1) mRNA in adult rat sensory ganglia. Neurosci. Lett. 250(3), 177-180 (1998).
82. Murata Y, Masuko S. Peripheral and central distribution of TRPV1, substance P and CGRP of rat corneal neurons. Brain Res. 1085(1), 87-94 (2006).
83. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol. 142(7), 1171-1181 (2004).
84. Nicoletti P, Trevisani M, Manconi M et al. Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig. Cephalalgia 28(1), 9-17 (2008).
85. Rudolf K, Eberlein W, Engel W et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4- dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-l-lysyl]- 4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J. Med. Chem. 48(19), 5921-5931 (2005).
86. Edvinsson L, Alm R, Shaw D et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur. J. Pharmacol. 434(1-2), 49-53 (2002).
87. Olesen J, Diener HC, Husstedt IW et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350(11), 1104-1110 (2004).
88. Salvatore CA, Hershey JC, Corcoran HA et al. Pharmacological characterization of TELCAGEPANT[N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2, 2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-1-yl) piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J. Pharmacol. Exp. Ther. 324(2), 416-421 (2008).
89. Paone DV, Shaw AW, Nguyen DN et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1Himidazo[4,5-b] pyridin- 1-yl) piperidine-1-carboxamide (MK-0974). J. Med. Chem. 50(23), 5564-5567 (2007).
90. Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol. Sci. 28(11), 580-587 (2007).
91. Ho TW, Mannix LK, Fan X et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70(16), 1304-1312 (2008).
92. Steiner TJ, Paemeleire K, Jensen R et al. European Headache Federation; lifting the burden: the global campaign to reduce the burden of headache worldwide; World Health Organization. European principles of management of common headache disorders in primary care. J. Headache Pain 8(Suppl. 1), 3-47 (2008). •• The most important document on primary headaches appeared after the International Headache Classification.
93. WHO: The World Health Report. Geneva: WHO. Chapter 2 (2001) www.who.int/whr/2001/chapter2/en/index.html
94. WHO: Lifting The Burden: the Global Campaign to reduce the burden of headache (2001) www.who.int/mental_health/neurology/headache/en